Bausch Health Companies Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$10.9Bnext fiscal year
FY EPS (est.)
$4.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Growth Quarterly12.0%Target: Reaffirming full-year 2026 consolidated revenue guidance of $10.67 billion to $10.92 billion
Bausch Health (excl. Bausch + Lomb) Revenue Quarterly1.3BTarget: $5.25 billion to $5.40 billion for FY 2026
Consolidated Adjusted EBITDA Attributable to Bausch Health Quarterly837MTarget: Reaffirming full-year 2026 Bausch Health (excl. Bausch + Lomb) Adjusted EBITDA of $2.875 billion to $2.950 billion
Watch Items
- Xifaxan Patent Litigation and Loss of Exclusivity (LOE)Trigger: Potential generic entry on or after January 1, 2028Action: Monitor legal developments, patent challenges, and FDA generic approvals closely to assess long-term EBITDA impact.
- Full Separation of Bausch + Lomb (BLCO)Trigger: Resolution of debt leverage covenants and tax-free distribution requirementsAction: Track management's progress on debt reduction and strategic options to unlock shareholder value through the BLCO spin-off.
- Larsucosterol Clinical DevelopmentTrigger: Phase 3 trial milestones for alcohol-associated hepatitisAction: Evaluate clinical trial data readouts and regulatory filing timelines to assess pipeline monetization potential.
Research as of 20 Jun 2026